Position in ENGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$16,731,284
-$11,544,526 QoQ
Shares Held
2,456,870
-21.5% QoQ
Ownership
3.67%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BRAIDWELL LP holds $1,531,675,908 across 50 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CAI |
Caris Life Sciences, Inc.
|
8,256,032 | $147,122,490 | |
| 2 | EWTX |
Edgewise Therapeutics, Inc.
|
1,996,965 | $81,136,687 | |
| 3 | SYRE |
Spyre Therapeutics, Inc.
|
879,467 | $78,079,080 | |
| 4 | KOD |
Kodiak Sciences Inc.
|
1,787,318 | $69,633,909 | |
| 5 | XENE |
Xenon Pharmaceuticals Inc.
|
1,131,452 | $68,294,442 | |
| 6 | GLUE |
Monte Rosa Therapeutics, Inc.
|
2,451,562 | $59,327,800 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
594,562 | $57,957,903 | |
| 8 | GENB |
Generate Biomedicines, Inc.
|
3,283,844 | $55,398,448 |
All Filings in ENGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16,731,284 | 2,456,870 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $28,275,810 | 3,131,319 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $15,478,958 | 2,266,319 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||